Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
Ensem Therapeutics
Ensem Therapeutics
Centre Oscar Lambret
National Institutes of Health Clinical Center (CC)
Mayo Clinic
Kivu Bioscience Inc.
National Cancer Institute (NCI)
Eastern Cooperative Oncology Group
Eli Lilly and Company
Neonc Technologies, Inc.
ViroMissile, Inc.
Rutgers, The State University of New Jersey
Arcus Biosciences, Inc.
Terremoto Biosciences Inc.
Bristol-Myers Squibb
Kaiser Permanente
Sichuan Enray Pharmaceutical Sciences Company
AstraZeneca
Tizona Therapeutics, Inc
National Institutes of Health Clinical Center (CC)
Genentech, Inc.
The Institute of Molecular and Translational Medicine, Czech Republic
Normunity AccelCo, Inc.
Eli Lilly and Company
Jonsson Comprehensive Cancer Center
University of Colorado, Denver
MacroGenics
Institut Curie
University of Oklahoma
Theravectys S.A.
Karolinska University Hospital
SystImmune Inc.
Daiichi Sankyo
Eli Lilly and Company
Adela, Inc
Radiopharm Theranostics, Ltd
ImmunityBio, Inc.
Ocellaris Pharma, Inc.
Fusion Pharmaceuticals Inc.
Innate Pharma
Brigham and Women's Hospital
National Institutes of Health Clinical Center (CC)
OncoNano Medicine, Inc.
University of Pittsburgh
Tanabe Pharma America, Inc.
Therorna
HiFiBiO Therapeutics
DualityBio Inc.
TScan Therapeutics, Inc.
TScan Therapeutics, Inc.
UNC Lineberger Comprehensive Cancer Center